

Registration number SC234197

Point-2-Point Genomics Limited

Abbreviated accounts

for the year ended 31 July 2008

FRIDAY



SJ8HTA9C

SCT

29/05/2009

197

COMPANIES HOUSE

Point-2-Point Genomics Limited

**Abbreviated balance sheet
as at 31 July 2008**

		2008		2007	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	2		507		228
Current assets					
Debtors		7,178		4,453	
Cash at bank and in hand		2,031		19,113	
		<u>9,209</u>		<u>23,566</u>	
Creditors: amounts falling due within one year		<u>(26,578)</u>		<u>(59,698)</u>	
Net current liabilities			<u>(17,369)</u>		<u>(36,132)</u>
Total assets less current liabilities			<u>(16,862)</u>		<u>(35,904)</u>
Creditors: amounts falling due after more than one year			<u>(6,000)</u>		<u>(6,000)</u>
Deficiency of assets			<u>(22,862)</u>		<u>(41,904)</u>
Capital and reserves					
Called up share capital	3		1,174		1,174
Share premium account			34,161		34,161
Profit and loss account			<u>(58,197)</u>		<u>(77,239)</u>
Shareholders' funds			<u>(22,862)</u>		<u>(41,904)</u>

The directors' statements required by Section 249B(4) are shown on the following page which forms part of this Balance Sheet.

The notes on pages 3 to 4 form an integral part of these financial statements.

Point-2-Point Genomics Limited

Abbreviated balance sheet (continued)

**Directors' statements required by Section 249B(4)
for the year ended 31 July 2008**

In approving these abbreviated accounts as directors of the company we hereby confirm:

(a) that for the year stated above the company was entitled to the exemption conferred by Section 249A(1) of the Companies Act 1985 ;

(b) that no notice has been deposited at the registered office of the company pursuant to Section 249B(2) requesting that an audit be conducted for the year ended 31 July 2008 and

(c) that we acknowledge our responsibilities for:


(1) ensuring that the company keeps accounting records which comply with Section 221, and

(2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the year then ended in accordance with the requirements of Section 226 and which otherwise comply with the provisions of the Companies Act relating to financial statements, so far as applicable to the company.

These abbreviated accounts have been prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to small companies .

The abbreviated accounts were approved by the Board on 28 May 2009 and signed on its behalf by

John Murray Harrison
Director

A handwritten signature in black ink, appearing to read 'John Murray Harrison', written over a horizontal line.

The notes on pages 3 to 4 form an integral part of these financial statements.

Point-2-Point Genomics Limited

Notes to the abbreviated financial statements for the year ended 31 July 2008

1. Accounting policies

1.1. Accounting convention

The accounts are prepared under the historical cost convention and in accordance with applicable accounting standards, and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2007).

1.2. Tangible fixed assets and depreciation

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows:

Fixtures, fittings and equipment	- 25% straight line per annum
-------------------------------------	-------------------------------

1.3. Deferred taxation

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more, or a right to pay less or to receive more, tax, with the following exceptions:

Provision is made for tax on gains arising from the revaluation (and similar fair value adjustments) of fixed assets, and gains on disposal of fixed assets that have been rolled over into replacement assets, only to the extent that, at the balance sheet date, there is a binding agreement to dispose of the assets concerned. However, no provision is made where, on the basis of all available evidence at the balance sheet date, it is more likely than not that the taxable gain will be rolled over into replacement assets and charged to tax only where the replacement assets are sold;

Provision is made for deferred tax that would arise on remittance of the retained earnings of overseas subsidiaries, associates and joint ventures only to the extent that, at the balance sheet date, dividends have been accrued as receivable;

Deferred tax assets are recognised only to the extent that the directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Deferred tax is measured on an undiscounted basis at the tax rates that are expected to apply in the periods in which timing differences reverse, based on tax rates and laws enacted or substantively enacted at the balance sheet date.

Point-2-Point Genomics Limited

Notes to the abbreviated financial statements for the year ended 31 July 2008

..... continued

2. Fixed assets	Tangible fixed assets £	
Cost		
At 1 August 2007	680	
Additions	599	
At 31 July 2008	1,279	
Depreciation		
At 1 August 2007	452	
Charge for year	320	
At 31 July 2008	772	
Net book values		
At 31 July 2008	507	
At 31 July 2007	228	
3. Share capital	2008 £	2007 £
Authorised		
1,098 Ordinary shares of £1 each	1,098	1,098
76 Preference shares of £1 each	76	76
	1,174	1,174
Allotted, called up and fully paid		
1,098 Ordinary shares of £1 each	1,098	1,098
76 Preference shares of £1 each	76	76
	1,174	1,174
Equity Shares		
1,098 Ordinary shares of £1 each	1,098	1,098
	1,098	1,098
Equity interest	1,098	1,098
Non-equity interest	76	76